KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Non-Current Assets (2016 - 2025)

Amgen has reported Non-Current Assets over the past 17 years, most recently at $61.5 billion for Q4 2025.

  • Quarterly results put Non-Current Assets at $61.5 billion for Q4 2025, down 2.04% from a year ago — trailing twelve months through Dec 2025 was $247.4 billion (down 3.21% YoY), and the annual figure for FY2025 was $61.5 billion, down 2.04%.
  • Non-Current Assets for Q4 2025 was $61.5 billion at Amgen, down from $62.3 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for AMGN hit a ceiling of $66.8 billion in Q4 2023 and a floor of $39.6 billion in Q3 2022.
  • Median Non-Current Assets over the past 5 years was $43.5 billion (2022), compared with a mean of $51.3 billion.
  • Biggest five-year swings in Non-Current Assets: surged 55.64% in 2023 and later dropped 6.01% in 2024.
  • Amgen's Non-Current Assets stood at $41.8 billion in 2021, then grew by 2.76% to $42.9 billion in 2022, then surged by 55.64% to $66.8 billion in 2023, then decreased by 6.01% to $62.8 billion in 2024, then dropped by 2.04% to $61.5 billion in 2025.
  • The last three reported values for Non-Current Assets were $61.5 billion (Q4 2025), $62.3 billion (Q3 2025), and $61.2 billion (Q2 2025) per Business Quant data.